OBJECTIVE: Heart failure is a major contributor to cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA), but little is known about myocardial structure and function in this population. This study was undertaken to assess the factors associated with progression to heart failure in patients with RA. METHODS: With the use of cardiac magnetic resonance imaging, measures of myocardial structure and function were assessed in men and women with RA enrolled in the Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis study, a cohort study of subclinical cardiovascular disease in patients with RA, in comparison with non-RA control subjects from a cohort enrolled in the Baltimore Multi-Ethnic Study of Atherosclerosis. RESULTS: Measures of myocardial structure and function were compared between 75 patients with RA and 225 frequency-matched controls. After adjustment for confounders, the mean left ventricular mass was found to be 26 gm lower in patients with RA compared with controls (P < 0.001), an 18% difference. In addition, the mean left ventricular ejection fraction, cardiac output, and stroke volume were modestly lower in the RA group compared with controls. The mean left ventricular end systolic and end diastolic volumes did not differ between the groups. In patients with RA, higher levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies and current use of biologic agents, but not other measures of disease activity or severity, were associated with significantly lower adjusted mean values for the left ventricular mass, end diastolic volume, and stroke volume, but not with ejection fraction. The combined associations of anti-CCP antibody level and biologic agent use with myocardial measures were additive, without evidence of interaction. CONCLUSION: These findings suggest that the progression to heart failure in RA may occur through reduced myocardial mass rather than hypertrophy. Both modifiable and nonmodifiable factors may contribute to lower levels of left ventricular mass and volume.
OBJECTIVE:Heart failure is a major contributor to cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA), but little is known about myocardial structure and function in this population. This study was undertaken to assess the factors associated with progression to heart failure in patients with RA. METHODS: With the use of cardiac magnetic resonance imaging, measures of myocardial structure and function were assessed in men and women with RA enrolled in the Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis study, a cohort study of subclinical cardiovascular disease in patients with RA, in comparison with non-RA control subjects from a cohort enrolled in the Baltimore Multi-Ethnic Study of Atherosclerosis. RESULTS: Measures of myocardial structure and function were compared between 75 patients with RA and 225 frequency-matched controls. After adjustment for confounders, the mean left ventricular mass was found to be 26 gm lower in patients with RA compared with controls (P < 0.001), an 18% difference. In addition, the mean left ventricular ejection fraction, cardiac output, and stroke volume were modestly lower in the RA group compared with controls. The mean left ventricular end systolic and end diastolic volumes did not differ between the groups. In patients with RA, higher levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies and current use of biologic agents, but not other measures of disease activity or severity, were associated with significantly lower adjusted mean values for the left ventricular mass, end diastolic volume, and stroke volume, but not with ejection fraction. The combined associations of anti-CCP antibody level and biologic agent use with myocardial measures were additive, without evidence of interaction. CONCLUSION: These findings suggest that the progression to heart failure in RA may occur through reduced myocardial mass rather than hypertrophy. Both modifiable and nonmodifiable factors may contribute to lower levels of left ventricular mass and volume.
Authors: J M Gardin; R McClelland; D Kitzman; J A Lima; W Bommer; H S Klopfenstein; N D Wong; V E Smith; J Gottdiener Journal: Am J Cardiol Date: 2001-05-01 Impact factor: 2.778
Authors: Hossein Bahrami; David A Bluemke; Richard Kronmal; Alain G Bertoni; Donald M Lloyd-Jones; Eyal Shahar; Moyses Szklo; João A C Lima Journal: J Am Coll Cardiol Date: 2008-05-06 Impact factor: 24.094
Authors: Abdou Elhendy; Arend F L Schinkel; Ron T van Domburg; Jeroen J Bax; Don Poldermans Journal: J Nucl Cardiol Date: 2004 Sep-Oct Impact factor: 5.952
Authors: Soko Setoguchi; Sebastian Schneeweiss; Jerry Avorn; Jeffrey N Katz; Michael E Weinblatt; Raisa Levin; Daniel H Solomon Journal: Am Heart J Date: 2008-06-17 Impact factor: 4.749
Authors: Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Jon T Giles; Moyses Szklo; Wendy Post; Michelle Petri; Roger S Blumenthal; Gordon Lam; Allan C Gelber; Robert Detrano; William W Scott; Richard A Kronmal; Joan M Bathon Journal: Arthritis Res Ther Date: 2009-03-10 Impact factor: 5.156
Authors: William Bradham; Michelle J Ormseth; Comfort Elumogo; Srikanth Palanisamy; Chia-Ying Liu; Mark A Lawson; Jonathan H Soslow; Nadine Kawel-Boehm; David A Bluemke; C Michael Stein Journal: J Rheumatol Date: 2018-04-15 Impact factor: 4.666
Authors: Joshua F Baker; Jon T Giles; David Weber; Mary B Leonard; Babette S Zemel; Jin Long; Said Ibrahim; Patricia P Katz Journal: Rheumatology (Oxford) Date: 2017-06-01 Impact factor: 7.580
Authors: John M Davis; Grace Lin; Jae K Oh; Cynthia S Crowson; Sara J Achenbach; Terry M Therneau; Eric L Matteson; Richard J Rodeheffer; Sherine E Gabriel Journal: Int J Cardiol Date: 2017-03-31 Impact factor: 4.164
Authors: Laura Geraldino-Pardilla; Cesare Russo; Jeremy Sokolove; William H Robinson; Afshin Zartoshti; Jenny Van Eyk; Justyna Fert-Bober; Joao Lima; Jon T Giles; Joan M Bathon Journal: Rheumatology (Oxford) Date: 2017-04-01 Impact factor: 7.580
Authors: Rachel H Mackey; Lewis H Kuller; Kevin D Deane; Brian T Walitt; Yue-Fang Chang; V Michael Holers; William H Robinson; Russell P Tracy; Mark A Hlatky; Charles B Eaton; Simin Liu; Matthew S Freiberg; Mehret Birru Talabi; Erik B Schelbert; Larry W Moreland Journal: Arthritis Rheumatol Date: 2015-09 Impact factor: 10.995
Authors: Elena Myasoedova; John M Davis; Cynthia S Crowson; Véronique L Roger; Barry L Karon; Daniel D Borgeson; Terry M Therneau; Eric L Matteson; Richard J Rodeheffer; Sherine E Gabriel Journal: Arthritis Rheum Date: 2013-07